SGRYSurgery Partners, Inc.
Is it safe?
Mostly sound, with a caveat: insiders buying, but heavy debt (BB) and big price swings.
Insiders were net buyers (+$161K, 90 days to Oct 8, 2026). SEC Form 4 filings: officers and directors must report their own trades within two business days.
Moderately leveraged. A rule of thumb on leverage, not a credit rating.
Large price swings, high volatility. Worst drawdown -83% · now 39% below its 52-week high.
Against the whole market›
Percentile against every name Ryufin tracks. Higher is better; the tick marks the middle of the market. Context, not one of the checks above.
Where this answer is blind. Altman sits structurally low for utilities and pipelines; Beneish runs high for fast growers, since sales growth alone lifts it; banks and REITs are excluded.
Can SGRY take a bad year?
Surgery Partners, Inc. carries $3.53B of net debt at 6.30× EBITDA: a heavy load to carry through a bad year.
Net debt · as at Q2 2026 · over four years of earnings before interest, tax and depreciation, heavy
- Net debt / EBITDA
- 6.30×
Net debt / EBITDA · 6.37× a year ago · the load is coming down
- Debt / equity
- 2.25×
Debt / equity
- Annualised volatility
- 49%
Annualised volatility · roughly twice as jumpy as the market
Details›
- Total debtQ2 2026
- $3.75B
- Cash and short-term investments
- $217M
- Net debt
- $3.53B
- EBITDA, trailing twelve months
- $561M
- Operating profit, trailing twelve months
- $384M
- Debt / equity
- 2.25×
- Total debt / EBITDA
- 6.69×
- Annualised volatilitytwo years of daily moves
- 49%
- Worst drawdown on file
- −83%
- Below its 52-week high
- 39%
Balance sheet from SEC filings; drawdown and volatility from end-of-day closes; Altman Z from the filed statements.